Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.42 |
| ▸ | FEN1 | P39748 | 6/20 | 0.42 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319022 | 0.78 | DHFR (0.50) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL21719315 | 0.78 | ALOX5AP (0.31) | ALOX5APFEN1 | |
| SCHEMBL24033682 | 0.77 | ALOX5AP (0.30) | ALOX5APFEN1 | |
| SCHEMBL15429579 | 0.77 | DHFR (0.41) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL9284172 | 0.77 | NUDT1 (0.44) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL10202044 | 0.76 | KDM4E (0.45) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL24858182 | 0.75 | DHFR (0.41) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL19770360 | 0.72 | DHFR (0.47) | ALOX5APFEN1DHFRNUDT1 | |
| SCHEMBL23966684 | 0.72 | POLB (0.34) | — | |
| SCHEMBL179347 | 0.72 | KDM4E (0.42) | ALOX5APFEN1DHFRNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-8658661-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | ALOX5AP 17/4885FEN1 3090/4885DHFR 172/4885 |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | ALOX5AP 24/4885FEN1 2717/4885DHFR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.